Overall rank by patents
#25,492
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 3 technology areas, active 2015–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
The verdict
Vascular holds 11 US patents across 3 technology areas, rank #25,492 of 50,000 tracked assignees.
Vascular Access Technologies, Inc. has been granted 11 US utility patents between 2015 and 2024, placing Vascular Access Technologies, Inc. at rank #25,492 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.0 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a US Corporation, Vascular Access Technologies, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Vascular sits between Valencia Bioscience, Inc. (11 patents, rank #25,488) and Versana Micro Inc. (11 patents, rank #25,496) - the closest US assignees by grant volume. The composite Innovation Score of 33.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 5 in the 2015–2019 window, a +20% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Vascular Access Technologies, Inc.'s 13.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Vascular Access Technologies, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Valencia Bioscience, Inc.
11 patents
Valeo Lighting Hubei Technical Center Co. Ltd.
11 patents
Valerion Therapeutics, LLC
11 patents
Vanguard Group, Inc.
11 patents
Vascular Graft Solutions Ltd.
11 patents
Ventus Therapeutics U.S., Inc.
11 patents
Veolia Nuclear Solutions, Inc.
11 patents
Versana Micro Inc.
11 patents
Vascular Access Technologies, Inc.
11 patents
What this shows Vascular holds 11 patents at rank #25,492, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Vascular's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
34 Top 55% higher than 45% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 9.1% |
| 2016 | 1 | 9.1% |
| 2017 | 1 | 9.1% |
| 2019 | 2 | 18.2% |
| 2020 | 1 | 9.1% |
| 2022 | 1 | 9.1% |
| 2023 | 3 | 27.3% |
| 2024 | 1 | 9.1% |
Top 3 of 3 technology areas
Overall rank by patents
#25,492
Across all tracked assignees
33.6 out of 100
How to use this portfolio
Vascular's 11 grants land it in the top 55% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.